Dendreon Rises After Winning Approval for Cancer Drug (Update2)
April 29 (Bloomberg) — Dendreon Corp. won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators. Shares surged the most in a year in New York trading.
Read more on Bloomberg
Terramed Alliance News Nearly half of all breast cancer patients experienced chronic pain two to three years after treatment and more than half felt discomfort, according to a study by Danish researchers published Tuesday in the Journal of the American Medical Association, the New York Times reports. The study found that women younger than age 40, those who underwent radiation treatment and those who had surgery to remove lymph nodes in the armpit are most likely to experience lingering pain.
Cancer patient service fears
THE new boss of Tasmania’s peak cancer advocacy group has raised fears a discussion paper looking at the future regulation of community transport threatens the lifesaving Transport2Treatment (T2T) bus service.
Read more on The Advocate